In:
Immunological Reviews, Wiley, Vol. 278, No. 1 ( 2017-07), p. 87-100
Abstract:
CD 69 has been known as an early activation marker of lymphocytes; whereas, recent studies demonstrate that CD 69 also has critical functions in immune responses. Early studies using human samples revealed the involvement of CD 69 in various inflammatory diseases including asthma. Moreover, murine disease models using Cd69 −/− mice and/or anti‐ CD 69 antibody (Ab) treatment have revealed crucial roles for CD 69 in inflammatory responses. However, it had not been clear how the CD 69 molecule contributes to the pathogenesis of inflammatory diseases. We recently elucidated a novel mechanism, in which the interaction between CD 69 and its ligands, myosin light chain 9, 12a and 12b (Myl9/12) play a critical role in the recruitment of activated T cells into the inflammatory lung. In this review, we first summarize CD 69 function based on its structure and then introduce the evidence for the involvement of CD 69 in human diseases and murine disease models. Then, we will describe how we discovered CD 69 ligands, Myl9 and Myl12, and how the CD 69‐Myl9 system regulates airway inflammation. Finally, we will discuss possible therapeutic usages of the blocking Ab to the CD 69‐Myl9 system.
Type of Medium:
Online Resource
ISSN:
0105-2896
,
1600-065X
DOI:
10.1111/imr.2017.278.issue-1
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
2038276-5
SSG:
12